Kinase Inhibitors in Genetic Diseases

Int J Mol Sci. 2023 Mar 9;24(6):5276. doi: 10.3390/ijms24065276.

Abstract

Over the years, several studies have shown that kinase-regulated signaling pathways are involved in the development of rare genetic diseases. The study of the mechanisms underlying the onset of these diseases has opened a possible way for the development of targeted therapies using particular kinase inhibitors. Some of these are currently used to treat other diseases, such as cancer. This review aims to describe the possibilities of using kinase inhibitors in genetic pathologies such as tuberous sclerosis, RASopathies, and ciliopathies, describing the various pathways involved and the possible targets already identified or currently under study.

Keywords: RAS pathway; Wnt pathway; genetics; kinase inhibitors; mTOR pathway.

Publication types

  • Review

MeSH terms

  • Humans
  • Signal Transduction
  • TOR Serine-Threonine Kinases* / metabolism
  • Tuberous Sclerosis* / drug therapy
  • Tuberous Sclerosis* / genetics

Substances

  • TOR Serine-Threonine Kinases

Grants and funding

This research received no external funding.